• linkedin
  • Increase Font
  • Sharebar

    AeroForm for soft tissue expansion

    The FDA OK’d marketing for the AeroForm (AirXpanders) device, a new wireless tissue expander system for post-mastectomy breast reconstruction patients, according to an FDA announcement late December 2016.

    Surgeons can use AeroForm for soft tissue expansion in two-stage breast reconstruction and to treat underdeveloped breasts and soft tissue deformities. The system puts patients in charge, by allowing them to use a dose controller to inflate the expander, a balloon-like device with a soft, expandable polymer shell.

    Dr. KluskaMichael S. Kluska, D.O., a cosmetic and plastic surgeon practicing in White Sulfur Springs, W.V. and president of the American Academy of Cosmetic Surgery, tells Cosmetic Surgery Times that he thinks AeroForm is a technologic leap for patients and physicians.

    “The patient is more integrated, and one of the most important parts of recovery for a patient, in my mind, is they are accountable, can take part in it and they feel they have control,” Dr. Kluska says.

    Using AeroForm also benefits surgeons who take insurance for payment because the patient can do the expanding without having to come into the office, according to Dr. Kluska.

    “We get a 90-day global period for placement of that expander. After that, the patient can come in one time or 100 times, and we can’t bill for it,” says Dr. Kluska, who has no conflicts of interest to report.

    NEXT: Device Details

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results